Matthew Del Giudice
Net worth: - $ as of 31/08/2026
Net worth: - $ as of 31/08/2026
Dr. Matthew P.
Del Giudice, MD, is an Independent Director at Telomir Pharmaceuticals, Inc. and an Independent Director at MIRA Pharmaceuticals, Inc. He is on the Board of Directors at Telomir Pharmaceuticals, Inc. and MIRA Pharmaceuticals, Inc. Dr. Del Giudice was previously employed as a Head-General Overnight Emergency Radiologist by The Cleveland Clinic Foundation.
He received his undergraduate degree from the University of Illinois At Urbana–Champaign and a doctorate degree from Stritch School of Medicine.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 21/07/2026 | 0 ( -.--% ) | - $ | 31/08/2026 | |
| 21/07/2026 | 0 ( -.--% ) | - $ | 31/08/2026 |
| Companies | Position | Start |
|---|---|---|
| MIRA PHARMACEUTICALS, INC. | Director/Board Member | 13/03/2024 |
| TELOMIR PHARMACEUTICALS, INC. | Director/Board Member | 12/08/2024 |
| Companies | Position | End |
|---|---|---|
The Cleveland Clinic Foundation
The Cleveland Clinic Foundation Medical/Nursing ServicesHealth Services Provides healthcare services | Corporate Officer/Principal | 01/05/2022 |
Active
Inactive
Listed companies
Private companies
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
| Private companies | 5 |
|---|---|
The Cleveland Clinic Foundation
The Cleveland Clinic Foundation Medical/Nursing ServicesHealth Services Provides healthcare services | Health Services |
Stritch School of Medicine
Stritch School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Illinois At Urbana–Champaign
University of Illinois At Urbana–Champaign Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
MIRA Pharmaceuticals, Inc.
MIRA Pharmaceuticals, Inc. Pharmaceuticals: OtherHealth Technology Develops and sells new molecular synthetic THC for the treatment of adult patients with anxiety and cognitive decline | Health Technology |
Telomir Pharmaceuticals, Inc.
Telomir Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops a novel small molecule as the first regulator of telomere length and genomic stability | Health Technology |
Select your edition
All financial news and data tailored to specific country editions